- IBDEI0Q3 ; ; 01-FEB-2022
- ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
- Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
- Q Q
- ;;^UTILITY(U,$J,358.3,11727,1,4,0)
- ;;=4^N02.2
- ;;^UTILITY(U,$J,358.3,11727,2)
- ;;=^5015513
- ;;^UTILITY(U,$J,358.3,11728,0)
- ;;=N02.3^^46^573^73
- ;;^UTILITY(U,$J,358.3,11728,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,11728,1,3,0)
- ;;=3^Recur & perst hematur w/ diffus mesangial prolif glomrlneph
- ;;^UTILITY(U,$J,358.3,11728,1,4,0)
- ;;=4^N02.3
- ;;^UTILITY(U,$J,358.3,11728,2)
- ;;=^5015514
- ;;^UTILITY(U,$J,358.3,11729,0)
- ;;=N02.4^^46^573^72
- ;;^UTILITY(U,$J,358.3,11729,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,11729,1,3,0)
- ;;=3^Recur & perst hematur w/ diffus endocaplry prolif glomrlneph
- ;;^UTILITY(U,$J,358.3,11729,1,4,0)
- ;;=4^N02.4
- ;;^UTILITY(U,$J,358.3,11729,2)
- ;;=^5015515
- ;;^UTILITY(U,$J,358.3,11730,0)
- ;;=N02.5^^46^573^77
- ;;^UTILITY(U,$J,358.3,11730,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,11730,1,3,0)
- ;;=3^Recurrent & perst hematur w/ diffuse mesangiocap glomrlneph
- ;;^UTILITY(U,$J,358.3,11730,1,4,0)
- ;;=4^N02.5
- ;;^UTILITY(U,$J,358.3,11730,2)
- ;;=^5015516
- ;;^UTILITY(U,$J,358.3,11731,0)
- ;;=N02.6^^46^573^74
- ;;^UTILITY(U,$J,358.3,11731,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,11731,1,3,0)
- ;;=3^Recurrent & perst hematur w/ dense deposit disease
- ;;^UTILITY(U,$J,358.3,11731,1,4,0)
- ;;=4^N02.6
- ;;^UTILITY(U,$J,358.3,11731,2)
- ;;=^5015517
- ;;^UTILITY(U,$J,358.3,11732,0)
- ;;=N02.7^^46^573^75
- ;;^UTILITY(U,$J,358.3,11732,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,11732,1,3,0)
- ;;=3^Recurrent & perst hematur w/ diffuse crescentic glomrlneph
- ;;^UTILITY(U,$J,358.3,11732,1,4,0)
- ;;=4^N02.7
- ;;^UTILITY(U,$J,358.3,11732,2)
- ;;=^5015518
- ;;^UTILITY(U,$J,358.3,11733,0)
- ;;=N02.8^^46^573^80
- ;;^UTILITY(U,$J,358.3,11733,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,11733,1,3,0)
- ;;=3^Recurrent & perst hematur w/ oth morphologic changes
- ;;^UTILITY(U,$J,358.3,11733,1,4,0)
- ;;=4^N02.8
- ;;^UTILITY(U,$J,358.3,11733,2)
- ;;=^5015519
- ;;^UTILITY(U,$J,358.3,11734,0)
- ;;=N02.9^^46^573^81
- ;;^UTILITY(U,$J,358.3,11734,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,11734,1,3,0)
- ;;=3^Recurrent & perst hematur w/ unsp morphologic changes
- ;;^UTILITY(U,$J,358.3,11734,1,4,0)
- ;;=4^N02.9
- ;;^UTILITY(U,$J,358.3,11734,2)
- ;;=^5015520
- ;;^UTILITY(U,$J,358.3,11735,0)
- ;;=N03.0^^46^573^18
- ;;^UTILITY(U,$J,358.3,11735,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,11735,1,3,0)
- ;;=3^Chr nephritic syndrome w/ minor glomerular abnormality
- ;;^UTILITY(U,$J,358.3,11735,1,4,0)
- ;;=4^N03.0
- ;;^UTILITY(U,$J,358.3,11735,2)
- ;;=^5015521
- ;;^UTILITY(U,$J,358.3,11736,0)
- ;;=N03.1^^46^573^17
- ;;^UTILITY(U,$J,358.3,11736,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,11736,1,3,0)
- ;;=3^Chr nephritic syndrome w/ focal & seg glomerular lesions
- ;;^UTILITY(U,$J,358.3,11736,1,4,0)
- ;;=4^N03.1
- ;;^UTILITY(U,$J,358.3,11736,2)
- ;;=^5015522
- ;;^UTILITY(U,$J,358.3,11737,0)
- ;;=N03.2^^46^573^14
- ;;^UTILITY(U,$J,358.3,11737,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,11737,1,3,0)
- ;;=3^Chr nephritic syndrome w/ diffuse membranous glomrlneph
- ;;^UTILITY(U,$J,358.3,11737,1,4,0)
- ;;=4^N03.2
- ;;^UTILITY(U,$J,358.3,11737,2)
- ;;=^5015523
- ;;^UTILITY(U,$J,358.3,11738,0)
- ;;=N03.3^^46^573^15
- ;;^UTILITY(U,$J,358.3,11738,1,0)
- ;;=^358.31IA^4^2
- ;;^UTILITY(U,$J,358.3,11738,1,3,0)
- ;;=3^Chr nephritic syndrome w/ diffuse mesangial prolif glomrlneph
- ;;^UTILITY(U,$J,358.3,11738,1,4,0)
- ;;=4^N03.3
- ;;^UTILITY(U,$J,358.3,11738,2)
- ;;=^5015524
- ;;^UTILITY(U,$J,358.3,11739,0)
- ;;=N03.4^^46^573^13
- --- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI0Q3 3786 printed Feb 18, 2025@23:19:56 Page 2
- IBDEI0Q3 ; ; 01-FEB-2022
- +1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
- +2 if 'DIFQR(358.3)
- QUIT
- FOR I=1:2
- SET X=$TEXT(Q+I)
- if X=""
- QUIT
- SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
- SET X=$EXTRACT(X,4,999)
- if $ASCII(Y)=126
- SET I=I+1
- SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
- if $ASCII(Y)=61
- SET Y=$EXTRACT(Y,2,999)
- XECUTE NO
- IF '$TEST
- SET @X=Y
- Q QUIT
- +1 ;;^UTILITY(U,$J,358.3,11727,1,4,0)
- +2 ;;=4^N02.2
- +3 ;;^UTILITY(U,$J,358.3,11727,2)
- +4 ;;=^5015513
- +5 ;;^UTILITY(U,$J,358.3,11728,0)
- +6 ;;=N02.3^^46^573^73
- +7 ;;^UTILITY(U,$J,358.3,11728,1,0)
- +8 ;;=^358.31IA^4^2
- +9 ;;^UTILITY(U,$J,358.3,11728,1,3,0)
- +10 ;;=3^Recur & perst hematur w/ diffus mesangial prolif glomrlneph
- +11 ;;^UTILITY(U,$J,358.3,11728,1,4,0)
- +12 ;;=4^N02.3
- +13 ;;^UTILITY(U,$J,358.3,11728,2)
- +14 ;;=^5015514
- +15 ;;^UTILITY(U,$J,358.3,11729,0)
- +16 ;;=N02.4^^46^573^72
- +17 ;;^UTILITY(U,$J,358.3,11729,1,0)
- +18 ;;=^358.31IA^4^2
- +19 ;;^UTILITY(U,$J,358.3,11729,1,3,0)
- +20 ;;=3^Recur & perst hematur w/ diffus endocaplry prolif glomrlneph
- +21 ;;^UTILITY(U,$J,358.3,11729,1,4,0)
- +22 ;;=4^N02.4
- +23 ;;^UTILITY(U,$J,358.3,11729,2)
- +24 ;;=^5015515
- +25 ;;^UTILITY(U,$J,358.3,11730,0)
- +26 ;;=N02.5^^46^573^77
- +27 ;;^UTILITY(U,$J,358.3,11730,1,0)
- +28 ;;=^358.31IA^4^2
- +29 ;;^UTILITY(U,$J,358.3,11730,1,3,0)
- +30 ;;=3^Recurrent & perst hematur w/ diffuse mesangiocap glomrlneph
- +31 ;;^UTILITY(U,$J,358.3,11730,1,4,0)
- +32 ;;=4^N02.5
- +33 ;;^UTILITY(U,$J,358.3,11730,2)
- +34 ;;=^5015516
- +35 ;;^UTILITY(U,$J,358.3,11731,0)
- +36 ;;=N02.6^^46^573^74
- +37 ;;^UTILITY(U,$J,358.3,11731,1,0)
- +38 ;;=^358.31IA^4^2
- +39 ;;^UTILITY(U,$J,358.3,11731,1,3,0)
- +40 ;;=3^Recurrent & perst hematur w/ dense deposit disease
- +41 ;;^UTILITY(U,$J,358.3,11731,1,4,0)
- +42 ;;=4^N02.6
- +43 ;;^UTILITY(U,$J,358.3,11731,2)
- +44 ;;=^5015517
- +45 ;;^UTILITY(U,$J,358.3,11732,0)
- +46 ;;=N02.7^^46^573^75
- +47 ;;^UTILITY(U,$J,358.3,11732,1,0)
- +48 ;;=^358.31IA^4^2
- +49 ;;^UTILITY(U,$J,358.3,11732,1,3,0)
- +50 ;;=3^Recurrent & perst hematur w/ diffuse crescentic glomrlneph
- +51 ;;^UTILITY(U,$J,358.3,11732,1,4,0)
- +52 ;;=4^N02.7
- +53 ;;^UTILITY(U,$J,358.3,11732,2)
- +54 ;;=^5015518
- +55 ;;^UTILITY(U,$J,358.3,11733,0)
- +56 ;;=N02.8^^46^573^80
- +57 ;;^UTILITY(U,$J,358.3,11733,1,0)
- +58 ;;=^358.31IA^4^2
- +59 ;;^UTILITY(U,$J,358.3,11733,1,3,0)
- +60 ;;=3^Recurrent & perst hematur w/ oth morphologic changes
- +61 ;;^UTILITY(U,$J,358.3,11733,1,4,0)
- +62 ;;=4^N02.8
- +63 ;;^UTILITY(U,$J,358.3,11733,2)
- +64 ;;=^5015519
- +65 ;;^UTILITY(U,$J,358.3,11734,0)
- +66 ;;=N02.9^^46^573^81
- +67 ;;^UTILITY(U,$J,358.3,11734,1,0)
- +68 ;;=^358.31IA^4^2
- +69 ;;^UTILITY(U,$J,358.3,11734,1,3,0)
- +70 ;;=3^Recurrent & perst hematur w/ unsp morphologic changes
- +71 ;;^UTILITY(U,$J,358.3,11734,1,4,0)
- +72 ;;=4^N02.9
- +73 ;;^UTILITY(U,$J,358.3,11734,2)
- +74 ;;=^5015520
- +75 ;;^UTILITY(U,$J,358.3,11735,0)
- +76 ;;=N03.0^^46^573^18
- +77 ;;^UTILITY(U,$J,358.3,11735,1,0)
- +78 ;;=^358.31IA^4^2
- +79 ;;^UTILITY(U,$J,358.3,11735,1,3,0)
- +80 ;;=3^Chr nephritic syndrome w/ minor glomerular abnormality
- +81 ;;^UTILITY(U,$J,358.3,11735,1,4,0)
- +82 ;;=4^N03.0
- +83 ;;^UTILITY(U,$J,358.3,11735,2)
- +84 ;;=^5015521
- +85 ;;^UTILITY(U,$J,358.3,11736,0)
- +86 ;;=N03.1^^46^573^17
- +87 ;;^UTILITY(U,$J,358.3,11736,1,0)
- +88 ;;=^358.31IA^4^2
- +89 ;;^UTILITY(U,$J,358.3,11736,1,3,0)
- +90 ;;=3^Chr nephritic syndrome w/ focal & seg glomerular lesions
- +91 ;;^UTILITY(U,$J,358.3,11736,1,4,0)
- +92 ;;=4^N03.1
- +93 ;;^UTILITY(U,$J,358.3,11736,2)
- +94 ;;=^5015522
- +95 ;;^UTILITY(U,$J,358.3,11737,0)
- +96 ;;=N03.2^^46^573^14
- +97 ;;^UTILITY(U,$J,358.3,11737,1,0)
- +98 ;;=^358.31IA^4^2
- +99 ;;^UTILITY(U,$J,358.3,11737,1,3,0)
- +100 ;;=3^Chr nephritic syndrome w/ diffuse membranous glomrlneph
- +101 ;;^UTILITY(U,$J,358.3,11737,1,4,0)
- +102 ;;=4^N03.2
- +103 ;;^UTILITY(U,$J,358.3,11737,2)
- +104 ;;=^5015523
- +105 ;;^UTILITY(U,$J,358.3,11738,0)
- +106 ;;=N03.3^^46^573^15
- +107 ;;^UTILITY(U,$J,358.3,11738,1,0)
- +108 ;;=^358.31IA^4^2
- +109 ;;^UTILITY(U,$J,358.3,11738,1,3,0)
- +110 ;;=3^Chr nephritic syndrome w/ diffuse mesangial prolif glomrlneph
- +111 ;;^UTILITY(U,$J,358.3,11738,1,4,0)
- +112 ;;=4^N03.3
- +113 ;;^UTILITY(U,$J,358.3,11738,2)
- +114 ;;=^5015524
- +115 ;;^UTILITY(U,$J,358.3,11739,0)
- +116 ;;=N03.4^^46^573^13
